Thomas Gajewski (34 results)

Condition: New. In.

Condition: New. This book describes recent ground-breaking developments in melanoma treatment in the arena of targeted therapeutics. The contents explore both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies. Editor(s): Gajewski, Thomas Frank; Hodi, F. Stephen. Series: Current Clinical Oncology. Num Pages: 392 pages, 14 black & white tables, biography. BIC Classification: MJCL. Category: (P) Professional & Vocational. Dimension: 235 x 155 x 23. Weight in Grams: 599. . 2014. Paperback. . . . .

Condition: New. pp. 392.

Condition: New.

Condition: New.

Taschenbuch. Condition: Neu. Targeted Therapeutics in Melanoma | Thomas F. Gajewski (u. a.) | Taschenbuch | Current Clinical Oncology | xiv | Englisch | 2014 | Humana | EAN 9781627038768 | Verantwortliche Person für die EU: Humana Press in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.

Paperback. Condition: Brand New. 392 pages. 9.25x6.10x0.92 inches. In Stock.

Condition: New. This book describes recent ground-breaking developments in melanoma treatment in the arena of targeted therapeutics. The contents explore both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies. Editor(s): Gajewski, Thomas Frank; Hodi, F. Stephen. Series: Current Clinical Oncology. Num Pages: 392 pages, 14 black & white tables, biography. BIC Classification: MJCL. Category: (P) Professional & Vocational. Dimension: 235 x 155 x 23. Weight in Grams: 599. . 2014. Paperback. . . . . Books ship from the US and Ireland.

Condition: New.

Condition: New. pp. 392.

Condition: New. This book describes recent ground-breaking developments in melanoma treatment in the arena of targeted therapeutics. The contents explore both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies. Editor(s): Gajewski, Thomas; Hodi, F. Stephen. Series: Current Clinical Oncology. Num Pages: 392 pages, 14 black & white tables, biography. BIC Classification: MJCL; MJK. Category: (P) Professional & Vocational. Dimension: 235 x 155 x 23. Weight in Grams: 748. . 2011. 2012. Hardback. . . . .

Condition: New. In.

Hardcover. Condition: Brand New. 1st edition. 377 pages. 9.25x6.25x1.00 inches. In Stock.

Condition: New. This book describes recent ground-breaking developments in melanoma treatment in the arena of targeted therapeutics. The contents explore both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies. Editor(s): Gajewski, Thomas; Hodi, F. Stephen. Series: Current Clinical Oncology. Num Pages: 392 pages, 14 black & white tables, biography. BIC Classification: MJCL; MJK. Category: (P) Professional & Vocational. Dimension: 235 x 155 x 23. Weight in Grams: 748. . 2011. 2012. Hardback. . . . . Books ship from the US and Ireland.

Paperback. Condition: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

Condition: As New. Unread book in perfect condition.

Hardcover. Condition: Like New. Like New. book.

Condition: As New. Unread book in perfect condition.

Condition: Sehr gut. XIV; 377 S.; Abb., graph. Darst. Sehr gutes Ex. - Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas-over-exposure to ultraviolet light-is well known, effective treatment has remained challenging; The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these groundbreaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies. This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers. // Part I Advances in Melanoma Biology -- Molecular Targets and Subtypes in Melanoma -- Michael A Davies -- Melanoma Genomics, -- Mohammed Kashani-Sabet -- Predictive Biomarkers as a Guide to Future Therapy -- Selection in Melanoma -- Thomas F Gajewski -- Part II Signaling Molecules as Molecular Targets -- KIT as a Therapeutic Target for Melanoma -- Nageatte Ibrahim and F Stephen Hodi -- Targeted Inhibition of B-Raf -- Paul B Chapman and Keith Flaherty -- The Notch and ß-Catenin Pathways -- John T Lee and Meenhard Herlyn -- STAT3 and Src Signaling in Melanoma -- Maciej Kujawski, Gregory Cherryholmes, -- Saul J Priceman, and Hua Yu -- Targeting the mTOR, PI3K, and AKT Pathways -- in Melanoma -- Kim A Margolin -- Targeting Apoptotic Pathways in Melanoma -- Peter Hersey and Xu Dong Zhang Anti-Angiogenesis Therapy in Melanoma -- Daniel S Chen -- Part III Rational Immunotherapy Approaches in Melanoma -- Melanoma Antigens Recognized by T Lymphocytes -- Nicolas van Baren, Jean-Francois Baurain, -- Francis Brasseur, and Pierre G Coulie -- Melanoma Vaccines -- Pedro Romero and Daniel E Speiser -- Adoptive Cell Therapy for the Treatment -- of Metastatic Melanoma -- Jessica Ann Chacon, Patrick Hwu, and Laszlo G Radvanyi -- Anti-CTLA-4 Monoclonal Antibodies -- Arvin S Yang and Jedd D Wolchok -- Anti-PD-1 and Anti-B7-Hl/PD-Ll Monoclonal Antibodies -- Evan J Lipson, Janis M Taube, Lieping Chen, and Suzanne L Topalian -- Treatment of Melanoma with Agonist Immune -- Costimulatory Agents -- Andrew Weinberg, Robert H Vonderheide, -- and Mario Sznol -- Novel Cytokines for Immunotherapy of Melanoma -- Shailender Bhatia and John A Thompson -- Modulating the Tumor Microenvironment -- Carl E Ruby and Howard L Kaufman. ISBN 9781617794063 Sprache: Deutsch Gewicht in Gramm: 600 Fadengehefteter Originalpappband.

Condition: new. Questo è un articolo print on demand.

Condition: new. Questo è un articolo print on demand.

Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas - over-exposure to ultraviolet light - is well known, effective treatment has remained challenging.The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies.This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers. 392 pp. Englisch.

Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Describes both established signal transduction inhibitors as well as emerging molecularly-guided immunotherapiesPlaces exciting developments in basic biological understanding into a practical clinical contextThe first book on .

Taschenbuch. Condition: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas ż over-exposure to ultraviolet light ż is well known, effective treatment has remained challenging.The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies.This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers.Springer-Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 392 pp. Englisch.

Gebunden. Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Describes both established signal transduction inhibitors as well as emerging molecularly-guided immunotherapiesPlaces exciting developments in basic biological understanding into a practical clinical contextThe first book on .

Condition: New. Print on Demand pp. 392.

Buch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas - over-exposure to ultraviolet light - is well known, effective treatment has remained challenging.The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies.This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers. 392 pp. Englisch.

Taschenbuch. Condition: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas - over-exposure to ultraviolet light - is well known, effective treatment has remained challenging.The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies.This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers.

Condition: New. PRINT ON DEMAND pp. 392.

Buch. Condition: Neu. Targeted Therapeutics in Melanoma | Thomas F. Gajewski (u. a.) | Buch | Current Clinical Oncology | xiv | Englisch | 2011 | Humana | EAN 9781617794063 | Verantwortliche Person für die EU: Humana Press in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu Print on Demand.